Targeted Resequencing and Systematic In Vivo Functional Testing Identifies Rare Variants in MEIS1 as Significant Contributors to Restless Legs Syndrome  by Schulte, Eva C. et al.
ARTICLE
Targeted Resequencing and Systematic In Vivo
Functional Testing Identifies Rare Variants in MEIS1
as Significant Contributors to Restless Legs Syndrome
Eva C. Schulte,1,2,22 Maria Kousi,3,22 Perciliz L. Tan,3 Erik Tilch,2,4 Franziska Knauf,2 Peter Lichtner,2,4
Claudia Trenkwalder,5,6 Birgit Ho¨gl,7 Birgit Frauscher,7 Klaus Berger,8 Ingo Fietze,9
Magdolna Hornyak,1,10,11 Wolfgang H. Oertel,12 Cornelius G. Bachmann,13,14 Alexander Zimprich,15
Annette Peters,16 Christian Gieger,17 Thomas Meitinger,2,4,18 Bertram Mu¨ller-Myhsok,18,19,20
Nicholas Katsanis,3,23 and Juliane Winkelmann1,2,4,18,21,23,*
Restless legs syndrome (RLS) is a common neurologic condition characterized by nocturnal dysesthesias and an urge to move, affecting
the legs. RLS is a complex trait, for which genome-wide association studies (GWASs) have identified common susceptibility alleles of
modest (OR 1.2–1.7) risk at six genomic loci. Among these, variants inMEIS1 have emerged as the largest risk factors for RLS, suggesting
that perturbations in this transcription factor might be causally related to RLS susceptibility. To establish this causality, direction of
effect, and total genetic burden of MEIS1, we interrogated 188 case subjects and 182 control subjects for rare alleles not captured by
previous GWASs, followed by genotyping of ~3,000 case subjects and 3,000 control subjects, and concluded with systematic function-
alization of all discovered variants using a previously established in vivo model of neurogenesis. We observed a significant excess of rare
MEIS1 variants in individuals with RLS. Subsequent assessment of all nonsynonymous variants by in vivo complementation revealed an
excess of loss-of-function alleles in individuals with RLS. Strikingly, these alleles compromised the function of the canonicalMEIS1 splice
isoform but were irrelevant to an isoform known to utilize an alternative 30 sequence. Our data link MEIS1 loss of function to the etio-
pathology of RLS, highlight how combined sequencing and systematic functional annotation of rare variation at GWAS loci can detect
risk burden, and offer a plausible explanation for the specificity of phenotypic expressivity of loss-of-function alleles at a locus broadly
necessary for neurogenesis and neurodevelopment.Introduction
Restless legs syndrome (RLS [MIM 102300]) is a common
neurologic condition with an age-dependent prevalence
of up to 10% in Europe and North America.1 It is character-
ized by an irresistible urge to move the legs accompanied
by disagreeable, often painful, sensations in the lower
limbs at night. Moving the affected legs or walking leads
to prompt but only temporary relief.1 As a consequence,
individuals suffer from persistent insomnia, leading to an
impairment of quality of life and mental health. RLS is
a highly familial trait but genetically complex, with esti-
mates of narrow-sense heredity between 54% and 69% as
derived from twin studies.2,3
Genome-wide association studies (GWASs) in large RLS
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Thity alleles at six loci that together explain about 7% of the
heritability.4 Among many models that can explain some
of the ‘‘missing heritability,’’5 we considered the possibility
that a collection of rare variants of strong effect, which
cannot be identified by means of GWASs,6,7 might be
a contributory factor. Although a single potentially causal
rare variant has been described in MEIS1 (MIM
601739),8,9 to date no variants of strong effect have been
established. Nonetheless, for some other complex genetic
diseases, such as diabetes or chronic inflammatory bowel
disease, rare variants have recently been identified within
known GWAS loci,10,11 supporting the concept of allelic
series in complex genetic disorders. We therefore sought
to assess the potential contribution of rare variants to
disease burden both by using standard statistical methods
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functionally annotated variants relevant to MEIS1 biology
(Figure S1 available online). For this purpose, we exploited
two major resources: a well-phenotyped, ethnically homo-
geneous RLS cohort and an experimentally tractable
method to assay MEIS1 functionality grounded on previ-
ously defined in vivo observations on the roles of this
protein in neurogenesis, wherein suppression of meis1 in
zebrafish embryos led to a quantitative reduction of the
optic tectum, a major site of neurogenesis in the devel-
oping brain, and malformation of rhombomeres 3 and 5,
which represent early hindbrain structures shown previ-
ously to be defective in the absence of meis1.12,13 Our
data showed a significant enrichment of rare variants
across both MEIS1 and also all seven RLS-associated genes.
Based upon population statistics alone, only one single
low-frequency variant in the 30 UTR (rs11693221) showed
significant association with RLS. However, the combinato-
rial usage of functional annotation and statistical analyses
highlighted a major contribution of loss-of-function vari-
ants in MEIS1 and suggested that rare alleles in this locus
pose significant RLS risk to individuals.Materials and Methods
Participants
Both case and control populations were entirely of German and
Austrian descent. In the case subjects, diagnosis was based on
the diagnostic criteria of the International RLS Study Group1 as
assessed in a personal interview conducted by an RLS expert. In
keeping with the previous GWASs,4,14 we excluded individuals
with secondary RLS due to uremia, dialysis, or anemia resulting
from iron deficiency. The presence of secondary RLS was deter-
mined by clinical interview, physical and neurological examina-
tion, blood chemistry, and nerve conduction studies whenever
deemed clinically necessary. Participants’ written informed con-
sent was obtained prior to the initiation of the study. The institu-
tional review boards of the contributing authors approved the
study. The primary review board was located in Munich at the
Bayerische A¨rztekammer and Technische Universita¨t Mu¨nchen.
Genotyping by High-Resolution Melting Curve
Analysis
In a first step, we used Idaho LightScanner high-resolutionmelting
curve analysis (Biofire) to screen the coding regions and exon/
intron boundaries of PTPRD (MIM 601598), BC034767, TOX3
(MIM 611416), BTBD9 (MIM 611237), MEIS1, and MAP2K5
(MIM 602520) for variants. Due to the high GC content, the
coding regions 510 bp of SKOR1 (MIM 611273) could not be
subjected to LightScanner analysis and were Sanger sequenced
instead. Included in the screening were 188 German RLS-affected
case subjects and 182 general population control subjects
belonging to the KORA cohort13 based in Southern Germany.
Where possible, the 188 case subjects used were half homozygous
and half heterozygous for the published risk alleles.4,14–16 The
same set of control subjects was used for all screening experiments.
MEIS1, TOX3, and BC034767 variants identified in the 188 case
subjects have already been published.4,8 In the case of an altered
melting pattern suggestive of variants, Sanger sequencing ensued
to identify the underlying variant. The same method was used to86 The American Journal of Human Genetics 95, 85–95, July 3, 2014screen the coding regions of MEIS1 isoforms 1 and 2 510 bp as
well as the 50 and 30 UTRs in 3,760 RLS case subjects of German
and Austrian descent (62.2 5 12.8 years; 30.8% male) and 3,542
general-population control subjects (55.1 5 13.8 years; 40.1%
male) belonging to the S4 and F4 surveys of KORA.17 For the dis-
covery sample, group comparisons between case and control sub-
jects were performed in R18 for each gene and each type of variant
separately, with and without the common risk allele genotype as
covariate, using logistic regression (logreg) of the phenotype on
aggregate minor allele counts of variants of each type.19 To ac-
count for a possible bias introduced by the comparison of different
sets of risk-genotype-selected cases to a constant set of unselected
controls, we performed ameta-analysis using rmeta to evaluate the
contribution of rare coding variants across all seven genes.
Empirical p values were calculated with 1,000 permutations of
the phenotype and assessing the ratio of p values equal to or
smaller than the p value belonging to the original phenotype.
For the large-scale screening of MEIS1, both logreg of the pheno-
type on number of variants as well as sequence kernel association
tests (SKAT)20 with and withoutMadsen-Browning weights21 were
performed. Empirical p values are based on 10,000 permutations
of the phenotype, calculating the ratio of test statistics equal to
or larger than the test statistic of the original phenotype.Genotyping by Mass Spectrometry
Genotyping was carried out on the MassARRAY system byMALDI-
TOF mass spectrometry with iPLEX Gold chemistry (Sequenom).
Primers were designed with AssayDesign v.3.1.2.2 with iPLEX
Gold default parameters. No assay could be designed for seven
variants, largely those located in the extremely GC-rich gene
SKOR1. Further, three assays failed two or more times and were,
therefore, not pursued further. Automated genotype calling was
carried out with SpectroTYPER v.3.4. Genotype clustering was
visually checked by an experienced evaluator. SNPs with a call
rate <90% were excluded. The genotyping sample consisted of
3,262 case subjects of German and Austrian descent (65.3 5
11.3 years; 29.3%male) and 2,944 general population control sub-
jects (56.15 13.3 years; 48.7% male) from the KORA F4 survey.17
For the most part, case and control subjects used in both geno-
typing approaches were drawn from the same samples. Both
logreg of the phenotype on number of variants as well as
SKATs20 with and without Madsen-Browning weights21 were
performed. Empirical p values are based on 200 permutations of
the phenotype, calculating the ratio of test statistics larger than
the test statistic of the original phenotype.In Vivo Complementation in Zebrafish Embryos,
In Situ Hybridization, and Whole-Mount
Immunostaining
Splice-blocking morpholinos (MOs) against meis1 and map2k5
were designed and obtained from Gene Tools. We injected 1 nl
of diluted MO (4 ng for meis1_MO1, 3 ng for meis1_MO2, and
5 ng for map2k5) and/or RNA (75 pg for meis1, 100 pg for
map2k5) into wild-type zebrafish embryos at the 1- to 2-cell stage.
To evaluate hindbrain organization, injected embryos were raised
until the 10- to 13-somite stage, corresponding to 14 to 16 hr post-
fertilization (hpf); they were then dechorionated and fixed in 4%
paraformaldehyde (PFA) overnight. Fixed embryos were trans-
ferred to 100% methanol at 20C for at least 2 hr and were
then processed after standard protocols22 using a digoxygenin-
labeled antisense riboprobe against krox20. For analysis of the
optic tectum, injected embryos were fixed overnight at 72 hpf in
4% PFA and stored in 100% methanol at 20C. For acetylated
tubulin staining, embryos were fixed in Dent’s fixative (80%
methanol, 20% DMSO) overnight at 4C. The embryos were per-
meabilized with proteinase K followed by postfixation with 4%
PFA. PFA-fixed embryos were washed first in PBS and subsequently
in IF buffer (0.1% Tween-20, 1% BSA in PBS) for 10 min at room
temperature. The embryos were incubated in blocking buffer
(10% FBS, 1% BSA in PBS) for 1 hr at room temperature. After
two washes in IF buffer for 10 min each, embryos were incubated
in the primary antibody (anti-acetylated tubulin [T7451, mouse,
Sigma-Aldrich], 1:1,000) in blocking solution, overnight at 4C.
After two additional washes in IF buffer for 10 min each, embryos
were incubated in the secondary antibody solution (Alexa Fluor
goat anti-mouse IgG [A21207, Invitrogen], 1:1,000) in blocking
solution, for 1 hr at room temperature.
For RNA rescue and overexpression experiments, the human
wild-type mRNAs of isoforms 1 (RefSeq accession number
NM_002398.2/ENST00000272369) and 2 (no RefSeq ID/
ENST00000381518) of MEIS1 as well as the canonical isoform of
MAP2K5 (RefSeq NM_145160.2/ENST00000178640) were cloned
into the pCS2þ vector and transcribed in vitro using the SP6 Mes-
sage Machine kit (Ambion). All variants identified in isoform 1 as
well as all additional variants only coding in isoform 2 plus two
functional null variants from isoform 1 (p.Ser204Thr [c.610T>A]
and p.Arg272His [c.815G>A]; both RefSeq NM_002398.2/
ENST00000272369) were introduced with Phusion high-
fidelity DNA polymerase (New England Biolabs) and custom-
designed primers. Additionally, a non-naturally occurring homeo-
box domain-dead variant of MEIS1 (p.Arg276Ala þ p.Asn325Ala
[c.826_827delinsGCþ c.973_974delinsGC]; RefSeqNM_002398.2/
ENST00000272369) was created. All the experiments were repeated
in triplicate and significance of the morphant phenotype was
judged with Student’s t test.Results
Variant Screening of Seven RLS GWAS Candidate
Genes
To assess low-frequency (1% < minor allele frequency
[MAF] < 5%) coding variation at the known RLS suscep-
tibility loci encompassing PTPRD, TOX3, BTBD9,
MEIS1, MAP2K5, SKOR1, and the noncoding RNA
BC034767,4,14–16 we screened the coding regions and
exon-intron boundaries (510 bp) in 188 German individ-
uals with RLS and 182 control subjects belonging to the
KORA population cohort13 based in Southern Germany. A
total of 49 variants with MAF < 5% were identified in case
and control subjects together (Table S1). When collapsed
across all seven genes, rare and low-frequency nonsynony-
mous variants showed a trend toward being more frequent
in case than in control subjects (39 in case subjects versus 24
in control subjects; p ¼ 0.103; logreg meta-analysis; odds
ratio [OR] ¼ 1.40). Nonsynonymous and synonymous
variants combined, however, showed a stronger enrich-
ment in individuals with RLS (77 case subjects versus 46
control subjects; p ¼ 0.023, logreg meta-analysis; OR ¼
1.51). Addition of the common risk allele genotype4,14–16
into the analysis as a covariate decreased the permutedThp value (nonsynonymous only: p ¼ 0.079; all variants:
p ¼ 0.008; n ¼ 1,000 permutations), suggesting that the
enrichment of rare variants across all loci is independent
of the common risk allele genotype. However, the degree
of interdependence between common and rare variants
differed between genes (Table S2).
Within MEIS1, synonymous or nonsynonymous vari-
ants with a MAF below 5% were present in nine case
subjects but only one control subject (p ¼ 0.021) although
no marked difference in the amount of variation was
obvious in any of the other genes (Table S1). Here, the
p value increased modestly after addition of the common
risk variant (rs2300478) as covariate (p ¼ 0.080; 1,000
permutations), indicating some interdependence of rare
and common alleles at the MEIS1 locus. Variants did not
seem to cluster within specific regions of the examined
genes (Figure S2).
Genotyping of Identified Low-Frequency and Rare
Variants
To assess a possible association with the RLS phenotype,
we next genotyped 39 of the 49 identified variants in
3,262 German and Austrian RLS case subjects (65.3 5
11.3 years; 29.3% male) and 2,944 KORA control subjects
(56.1 5 13.3 years; 48.7% male). Of the 49 variants,
10 could not be included for technical reasons (see
Material and Methods section above). Although variants
(either altogether or only nonsynonymous ones) with
MAF < 5% and MAF < 1% were not significantly enriched
in RLS, we observed a distinct excess of very rare variants
with a KORA-derived MAF < 0.1% (total: 57 case versus
16 control subjects, p ¼ 4.99 3 104, OR ¼ 2.50; non-
synonymous only: 23 case versus 5 control subjects, p ¼
0.0019; OR ¼ 3.92; logreg; Figure 1).
We then went on to assess whether more sophisticated
tests used to analyze rare variant associations of bidirec-
tional effects (SKAT)20 and differing allele frequency
(SKAT with Madsen-Browning weights)21 would change
the association signal. However, although frequency-
weighted results were still superior to unweighted results
in most cases, overall SKAT analysis led to an increase in
association p values both for the joined analysis across all
loci as well as for MEIS1 alone (Table S2).
We next asked whether this signal is distributed across
all seven tested genes, or whether a specific subset of tested
loci cause the apparent enrichment of rare nonsynony-
mous variation in individuals with RLS. A significant asso-
ciation with RLS was observed forMEIS1; the aggregate risk
conferred by the variants showed a large increase as we
transitioned from rare (MAF < 1%) to very rare (MAF <
0.1%) (Figure 1). More specifically, rare variants with
MAF < 1% (total: 116 case subjects versus 67 control sub-
jects, p ¼ 0.0064, OR ¼ 1.51; nonsynonymous only: 39
versus 14, p ¼ 0.0024, OR ¼ 2.46) and MAF < 0.1%
(both total and nonsynonymous only: 9 versus 1: p ¼
0.014; OR ¼ 8.14; Figure 1) were seen more fre-
quently in cases than in controls. SKAT (all: p ¼ 0.049;e American Journal of Human Genetics 95, 85–95, July 3, 2014 87
Figure 1. Excess of Rare Coding Variants
at RLS-Associated GWAS Loci
Frequency assessment of 39 low-frequency
and rare variants identified in the coding
sequences of seven genes associated with
RLS4,14–16 in 3,262 case subject and 2,944
control subjects revealed an excess of
both overall (A) and nonsynonymous (B)
variants with MAF < 0.1% across all exam-
ined loci. The same held true for the overall
(C) and nonsynonymous (D) variants at
the MEIS1 locus.nonsynonymous only: p ¼ 0.009) and Madsen-Browning-
weighted SKAT (all: p ¼ 0.019; nonsynonymous only: p ¼
0.029; 10,000 permutations each) substantiated this
finding (Table S2). No low-frequency coding variants
with MAF between 1% and 5% were found within the
coding regions of MEIS1.
After exclusion of MEIS1, logreg (all variants: p ¼ 0.009;
nonsynoymous only: p ¼ 0.024; 2,000 permutations) for
variants with MAF < 0.1% and SKAT using Madsen-
Browning weights (all variants: p ¼ 0.019; nonsynony-
mous only: p ¼ 0.019; 100 permutations) showed a
nominally significant enrichment across all other six
genes. In PTPRD alone, rare variants of all classes were
also encountered more frequently in individuals with
RLS (all variants withMAF< 0.1%: p¼ 9.993 104, logreg;
all variants: p¼ 0.029, SKATwith MB) whereas this enrich-
ment was not observed for nonsynonymous variants
only. Of note, several individual rare variants in MEIS1
(p.Arg272His [c.815G>A] and p.Met453Thr [c.1359T>C]
[ENST00000381518]), TOX3 (p.Ala233Ala [c.699T>C];
RefSeq NM_001080430.2/ENST00000219746), and PTPRD
(c.5514C>G and p.Pro278Pro [c.834T>G]; both RefSeq
NM_002839.3/ENST00000381196) were associated nomi-
nally with RLS in the large case/control sample; however,
associations did not withstand correction for multiple
testing (Table S1).
Assessment of Rare Variation in MEIS1
The excess of low-frequency and rare variants at RLS-
associated GWAS loci was most pronounced for MEIS1.
Therefore, we sought to expand our analysis to a
more comprehensive investigation of genetic variation
with regard to frequency and location within MEIS1 by
screening the coding regions 510 bp as well as the 50
and 30 UTRs for variants with MAF < 5% in 3,760 German88 The American Journal of Human Genetics 95, 85–95, July 3, 2014and Austrian RLS case subjects
(62.2 5 12.8 years; 30.8% male) and
3,542 KORA control subjects (55.1 5
13.8 years; 40.1% male). We iden-
tified a total of 75 such variants
(Tables S3 and S4); 28 of these lie in
either the canonical isoform 1
(ENST00000272369) or a longer iso-
form 2 (ENST00000398506) of MEIS1
that encodes an alternate start siteand an alternate C terminus. All synonymous and
nonsynonymous variants identified in the initial
screening of 188 case subjects and 182 control subjects
were observed again.
Overall, we observed an excess of variants with MAF <
5% across all examined regions of MEIS1 (1,383 variant
counts in case subjects versus 606 in control subjects,
p ¼ 1.04 3 1061; not permuted), which was driven
primarily by a low-frequency variant, rs11693221, in the
30 UTR (MAFcases ¼ 13.55%, MAFcontrols ¼ 3.58%; p ¼
1.27 3 1089; OR ¼ 4.42 [95% CI: 3.83–5.11]; not
permuted; Figure 2, Tables S3 and S4). After exclusion of
this variant, the remainder of individuals with low-
frequency and rare variants across all regions of MEIS1
was similar in case and control subjects (432 versus 396;
p ¼ 0.68). However, stratification of variants according
to their localization showed an excess of rare variants
with MAF < 5% in the 50 UTR (16 case subjects versus 2
control subjects; logreg: p ¼ 0.001, OR ¼ 7.56; SKAT:
p ¼ 0.01; SKAT with MB: p ¼ 0.006) and among nonsyn-
onymous variants in isoform 2 (34 case subjects versus
15 control subjects; logreg: p ¼ 0.007, OR ¼ 2.31;
SKAT: p ¼ 0.004; SKAT with MB: p ¼ 0.0005) (Figure 2,
Table S3).
Functional Analysis of Rare Nonsynonymous Variants
in MEIS1 by In Vivo Complementation in Zebrafish
Embryos
Resequencing of any locus is certain to reveal rare variants
in both case and control subjects which, bereft of a means
of preselecting for variants relevant to protein function,
can dampen or extinguish bona fide association signals.
We, therefore, considered a paradigm grounded on prior
knowledge of MEIS1 to test whether each of the rare
discovered variants in our study have an effect on function
Figure 2. Variant Screening of the Cod-
ing Regions and UTRs of MEIS1 in 3,760
Individuals with RLS and 3,542 KORA
Control Subjects
Stratification according to variant localiza-
tion shows an excess of rare variants in
both the 50 UTR and among nonsynony-
mous coding variants. Low-frequency and
rare variants in the 30 UTR were also more
frequent in case subject than in control
subjects. No difference was observed in
the number of individuals carrying synon-
ymous coding or (near-) splice variants.and to then use this information to assess the burden of
deleterious genetic lesions in our case/control RLS study.
During zebrafish development, suppression of meis1 has
been shown to impact neurogenesis, a phenotype captured
prominently by the quantitative reduction of the size of
the optic tectum 72 hpf12 as well as the disruption of hind-
brain patterning at 14 hpf.13 We first tested the ability of
human MEIS1 mRNA to rescue the optic tectum size
phenotype and to thus establish a baseline assay for the
evaluation of the identified nonsynonymous variants. To
this end, we designed two independent MOs that target
different exon-intron splice junctions of the endogenous
zebrafish meis1. Both MOs gave rise to the same pheno-
type, bolstering our confidence in the specificity of the
assay: we observed a reduction of the size of the optic
tectum by ~30%when injecting 4 ng ofmeis1_MO1 target-
ing exon-intron boundary 2, and by ~20% when injecting
3 ng of a previously characterized MO (meis1_MO2)
against the acceptor site of exon 223 (Figures S3 and S4).
In both cases, the phenotype was rescued significantly
and reproducibly (p < 0.0001; performed in triplicate,
scored blind to injection cocktail) by coinjection with 75
pg of human capped MEIS1 mRNA (Figures S3 and S4).
The optic tectum phenotype could be rescued by either
the canonical MEIS1 isoform or by an isoform utilizing
an alternative 30 terminus. By contrast, injection of
the ‘‘domain-dead’’ human mRNA (MEIS1_DD) bearing
two variants engineered to ablate DNA binding ability
(p.Arg276AlaþAsn325Ala) was indistinguishable from
MO alone (p < 0.68). As a test of the relevance of the
phenotype to RLS, MO suppression of map2k5, another
GWAS-associated RLS gene, yielded a similar phenotype
with regard to the size of the optic tectum, which was
also specific as it could be rescued by coinjection with
human MAP2K5 mRNA (Figure S5).
Given these data, we proceeded to perform in vivo
complementation assays on all 13 nonsynonymous
coding variants identified in isoform 1, as well as in the 4
nonsynonymous variants that lie in the unique sequence
of isoform 2 (Figure 3, Table S4), wherein human mRNAThe American Journal of Hbearing one test variant was coin-
jected with MO and compared to the
rescue ability of WT mRNA (n ¼ at
least 51 embryos tested per injection,Figure 3 and Tables S5 and S6). We classified variants
as benign (rescue indistinguishable from WT), hypo-
morphs (mutant rescue significantly worse than WT but
better than MO alone), or functionally null (indistinguish-
able from MO alone). Among the 13 variants of isoform 1,
we identified three benign, four hypomorphic, and six null
variants (Figures 3 and 4). Overexpression of MEIS1 WT
mRNA or mRNAs harboring each of the 13 variants had
no effect on optic tectum size (Figure S6).
Layering these data over the incidence and distribution
of these variants in our case/control data set, we found a
significant excess of functionally null variants in individ-
uals with RLS compared to control subjects (14 in case
subjects versus 2 in control subjects; p ¼ 0.0012; OR ¼
7.48 [95% CI: 1.68–33.40]) (Figures 3 and 5) whereas
hypomorphic (2 in case subjects versus 4 in control
subjects; p > 0.05) and benign (2 in cases subject versus
2 in control subjects; p > 0.05) variants showed similar
distributions in case and control subjects.
To corroborate these data, we designed a second assay at
an earlier developmental time point, grounded on the
known requirement of meis1 for the organization of the
hindbrain; in triplicate experiments, ~30% of the embryos
suppressed for meis1 developed hindbrain defects that
reproduced previously reportedmeis1 phenotypes.13 These
consisted of significant widening of rhombomere 3 and/or
5 (r3 and r5); shortening of the distance between r3 and r5;
thinning of either one of those structures; or absence of
r3 and/or r5 altogether (Figure 4). This phenotype was
rescued by coinjection with 75 pg of WT human MEIS1
mRNA (p ¼ 0.045). Assessment of six variants from our
series (three variants scored as null and three variants
scored as benign in the optic tectum assay) and blind
triplicate scoring confirmed this result: p.Ser204Thr,
p.His239Tyr (c.715C>T), and p.Arg272His were verified
as null variants and p.Ala122Val (c.365C>T), p.Ser175Asn
(c.524G>A), and p.Met366Leu (c.1096A>T) were validated
as benign (all RefSeq NM_002398.2/ENST00000272369).
By contrast, all four nonsynonymous variants exclusive
to isoform 2 scored benign in our assay. Strikingly, twouman Genetics 95, 85–95, July 3, 2014 89
Figure 3. Functional Assessment of Rare Nonsynonymous Variants in MEIS1 by In Vivo Complementation in Zebrafish Embryos
(A) Location and frequency of nonsynonymous MEIS1 variants examined in zebrafish. Variants found in case subjects are given above
the gene, those found in control subjects below. The short, canonical isoform 1 ofMEIS1 is given in dark gray (ENST00000272369); the
additional amino acids in the longer isoform 2 in light gray (ENST00000398506).
(legend continued on next page)
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variants found to be functional nulls in the isoform 1
complementation assay (p.Ser204Thr and p.Arg272His)
were able to fully rescue the tectum size phenotype in iso-
form 2 (Figures 5 and S6), suggesting that the contribution
of rare variants to RLS is mediated specifically by reduced
activity of MEIS1 isoform 1-encoded protein.Discussion
Previous GWASs have established the genomic locus en-
compassing MEIS1 as the most significant susceptibility
region for RLS.4,14 The most likely candidate gene in this
region is MEIS1, a TALE homeobox transcription factor
known to be involved in specifying spinal motor neuron
pool identity and connectivity24 as well as proximo-distal
limb patterning25 and expressed in forebrain neurons
and astrocytes26 during embryonic development. A com-
mon RLS-linked intronic variant in MEIS1 was also shown
to induce differential forebrain enhancer activity during
development.27 Additional studies in the context of RLS
have suggested a link betweenMEIS1 and iron metabolism
in the central nervous system.28,29
The excess of rare alleles of functional effect in RLS case
subjects compared to control subjects shown here substan-
tiates MEIS1 as the causal genetic factor underlying the
observed associations. Moreover, it implicates loss of func-
tion as the underlying mechanism, at least with regard to
rare variants. We also observed a new association with a
low-frequency variant (rs11693221) located in the 30 UTR
of the ENSEMBL-derived canonical isoform 1 of MEIS1
(ENST00000272369) that represents the largest single-
allele genetic risk factor for RLS identified to date. In the
1000 Genomes data,30 the linkage disequilibrium (LD, r2)
between rs11693221 and the most significantly associated
common variant within MEIS1 (rs12469063)4,14 is low
(r2 ¼ 0.080). In the same data set,30 rs11693221 is in
high LD (r2 > 0.8) solely with a single low-frequency
variant (rs113851554, r2 ¼ 0.83). rs113851554 is located
within a highly conserved noncoding region in intron 8
and has previously also been shown to be associated with
RLS in a Canadian case/control sample.29 Follow-up ana-
lyses are needed to fully dissect all functional effects under-
lying the MEIS1 association signal.
Nonetheless, the finding of an associated low-frequency
variant (rs11693221) in the 30 UTR of isoform 1 in
conjunction with the observed excess of rare variants in
the 50 UTR of MEIS1 in individuals with RLS implicates(B) At 72 hpf, zebrafish larvae were stained as whole mounts using an
was measured for phenotypic read out. Control, morpholino injectio
The lower panels illustrate the effects of different alleles tested.
(C) Quantification of optic tectum area in zebrafish larvae at 72 hp
difference with regard to the MO injection, hypomorphic alleles a
the rescue (MO plus WT) injection, and null alleles are significantly
as determined by Student’s t test. Color of asterisks as follows: blue, M
red, allele versus WT rescue. Abbreviations are as follows: MO, mor
across all examined embryos.
Ththe UTRs in disease pathogenesis, potentially through
regulating expression and/or mRNA stability. The excess
of rare noncoding variants in the 100 bp surrounding the
exons of nine genes associated with asthma31 and the
fact that fine-mapping studies located about 22% of 36
GWAS association signals for celiac disease to either the
50 or the 30 noncoding regions (UTRs and several kilobases
up- or downstream)32 could indicate that these regions are
indeed important in the context of complex genetic
diseases and might be overlooked by the current surge of
whole-exome sequencing studies.
The functional experiments conducted in zebrafish
allowed us to differentiate between potentially benign
and pathological sequence variation and thereby increased
both effect size and significance levels observed in burden
testing. Moreover, the identified rare nonsynonymous
MEIS1 variants, which showed an effect on optic tectum
size in zebrafish embryos, were restricted to isoform 1 of
MEIS1 (ENST00000272369). Previous studies have demon-
strated that rare variants can exhibit isoform-specific
effects on a given phenotype, such as in the case of
DNAJB6 in limb-girdle muscular dystrophy.33 Because the
pathophysiology of RLS is just beginning to be elucidated,
it will be of importance to see when and where this isoform
of MEIS1 is expressed as the temporal and spatial expres-
sion patterns of the different MEIS1 transcripts are
currently unknown. Given our observations, we speculate
that understanding the differential biological roles of
isoform 1 will help dissect the subset of MEIS1 functions
relevant to the etiopathology of RLS.
Recent studies have implicated allelic series of variants of
different frequency and effect sizes at loci identified in the
context of GWASs in complex genetic diseases. In single
cases, individual rare variants were shown to be associated
with the phenotype11,34,35 whereas in other cases it was
the collective of rare variation either within a single
gene10 or across a number of GWAS-identified loci.36,37
Our data substantiate this role of the whole of genetic
variation, from common to low-frequency to rare
variation, at a GWAS-identified locus in the genetic
architecture of a complex genetic disease. Interestingly,
the addition of synonymous variants to the burden
analyses yielded a more significant enrichment of rare
variants in many situations. Whether this is due to
increased power, fine-scale population substructure, arti-
ficial signal amplification driven by high LD between
the synonymous and the nonsynonymous or causal vari-
ants, or a true causal contribution of rare synonymousantibody against acetylated tubulin and the size of the optic tecta
n, and rescue by humanWTmRNA are shown in the upper panels.
f (n ¼ at least 51 per genotype). Benign alleles show a significant
significant difference with regard to both the MO injection and
different from the rescue only. Asterisks denote significance levels
O versus control; green, rescue versus MO; black, allele versus MO;
pholino; WT, wild-type. Error bars represent standard deviations
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Figure 4. Functional Assessment of Null and Benign MEIS1 Variants by In Vivo Complementation in Zebrafish Embryos and Evalua-
tion of Hindbrain Patterning
(A–E) At 14–16 hpf, developing zebrafish embryos were evaluated for the integrity of rhombomeres 3 and 5 (r3 and r5) by in situ
hybridization with a riboprobe against krox20. Upon disruption of meis1, we observed rhombomeric defects that involved widening
of the evaluated structures (B and D) or shortening of the distance between r3 and r5 (D), as well as thinning or absence of the evaluated
structures.
(F) Quantification showing that the aberrant phenotypes were especially pronounced in themorphant embryos and embryos coinjected
with MOþnull mRNA (nR 26 embryos per genotype). Abbreviations are as follows: MO, morpholino; WT, wild-type.variation as was recently reported for sporadic Alzheimer
disease38 cannot be ascertained within the bounds of
this study. We also note that we were unable to establish
a single rare variant of large effect involved in RLS at
the examined loci, possibly due to a lack of power in
sight of the large amount of background rare genetic
variation and the excess of singletons known to exist in
the human genome.39–41 However, systematic functional
annotation of such singletons has improved our interpre-
tative ability and has suggested that, in addition to the
risk conferred by common and low-frequency alleles,
rare variants contribute significantly to the genetic
burden in RLS. Our data are consistent with previous ob-
servations wherein the rarer a genetic variant, the more
likely it is to harbor a functional effect42 and extends
these to a disease context. It is particularly notable that,
subsequent to functional tagging of alleles, we observed
association with RLS only for functionally null variants,92 The American Journal of Human Genetics 95, 85–95, July 3, 2014but not for hypomorphs, potentially intimating a
threshold effect on total MEIS1 function necessary to
drive pathology. Nonetheless, although our positive and
negative controls for the in vivo complementation assay
support previously reported high specificity and sensi-
tivity for the approach,43 and despite the fact that
we achieved full concordance of allele effect tagging
by two independent in vivo complementation assays, it
will be important to validate our observations further in
an independent model system; the evaluation of the
two functionally null variants MEIS1 p.Arg272His and
p.Gln353His (c.1059G>C) (both RefSeq NM_002398.2/
ENST00000272369) found primarily or exclusively in
case subjects, located in the homeobox and transcription
activation domains, respectively, in animal models could
prove worthwhile to establish their relevance to the RLS
phenotype and to further explore the pathophysiology
of the disorder.
Figure 5. Functional Annotation of Rare,
Nonsynonymous Variants in Isoforms 1
and 2 of MEIS1 According to the
Effect on Optic Tectum Size in Zebrafish
Embryos
When tested inMEIS1 isoform 1, an excess
of rare null alleles was present among indi-
viduals with RLS. When tested in isoform
2, none of the variants show a functional
effect, suggesting an isoform specificity
with regard to a potential involvement in
RLS. Numbers in parentheses behind
variants indicate the total variant count
in either case subjects or control subjects.
If no number is given, the variant is a
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